{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:25:03Z","timestamp":1794349503686,"version":"4.9.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"National Institutes of Health Fogarty International Center","doi-asserted-by":"publisher","award":["U01AI069919"],"award-info":[{"award-number":["U01AI069919"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.eclinm.2025.103584","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:59:20Z","timestamp":1761861560000},"page":"103584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Association between transitioning to a dolutegravir-based regimen and risk of incident hypertension in adults with HIV in West Africa: a multicentre target trial emulation study"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3765-8212","authenticated-orcid":false,"given":"Romain","family":"Millot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Tiendrebeogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Ezechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armel","family":"Poda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Minga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Malateste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igho","family":"Ofotokun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier K.","family":"Ekouevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Jaquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eclinm.2025.103584_bib1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/COH.0000000000000298","article-title":"Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population","volume":"11","author":"Wandeler","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.eclinm.2025.103584_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102255","article-title":"The burden of non-communicable diseases among people living with HIV in Sub-Saharan Africa: a systematic review and meta-analysis","volume":"65","author":"Moyo-Chilufya","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103584_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11904-016-0301-4","article-title":"Recent insights into cardiovascular disease (CVD) risk among HIV-infected adults","volume":"13","author":"Kaplan","year":"2016","journal-title":"Curr HIV AIDS Rep"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103584_bib4","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1002\/jmv.27028","article-title":"Alteration of type I interferon response is associated with subclinical atherosclerosis in virologically suppressed HIV-1-infected male patients","volume":"93","author":"Santinelli","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.eclinm.2025.103584_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/HIV.S275314","article-title":"Antiretroviral therapy-associated metabolic complications: review of the recent studies","volume":"12","author":"Thet","year":"2020","journal-title":"HIV"},{"key":"10.1016\/j.eclinm.2025.103584_bib6","year":"2018"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103584_bib7","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.eclinm.2025.103584_bib8","series-title":"Update on the transition do dolutegravir-based antiretroviral therapy : report of a WHO meeting","year":"2022"},{"key":"10.1016\/j.eclinm.2025.103584_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1008335","article-title":"Cardiovascular diseases in Africa in the twenty-first century: gaps and priorities going forward","volume":"9","author":"Minja","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.eclinm.2025.103584_bib10","series-title":"Confronting world's number one killer","author":"Di Cesare","year":"2023"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103584_bib11","doi-asserted-by":"crossref","first-page":"e1375","DOI":"10.1016\/S2214-109X(19)30374-2","article-title":"Burden of non-communicable diseases in Sub-Saharan Africa, 1990\u20132017: results from the global burden of disease study 2017","volume":"7","author":"Gouda","year":"2019","journal-title":"Lancet Global Health"},{"issue":"23","key":"10.1016\/j.eclinm.2025.103584_bib12","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1161\/CIRCULATIONAHA.105.563452","article-title":"Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study","volume":"112","author":"Steyn","year":"2005","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103584_bib14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103584_bib15","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","article-title":"Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon","volume":"7","author":"Calmy","year":"2020","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103584_bib16","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/cid\/ciad285","article-title":"Cardiovascular diseases and exposure to integrase inhibitors: causal interpretation of treatment effect in observational studies","volume":"77","author":"Costagliola","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103584_bib17","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(22)00094-7","article-title":"Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium Neesgaard, Bastian et al","volume":"9","year":"2022","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103584_bib18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/cid\/ciad286","article-title":"Impact of integrase inhibitors on cardiovascular disease events in people with human immunodeficiency virus starting antiretroviral therapy","volume":"77","author":"Surial","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103584_bib19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/hiv.13273","article-title":"Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium","volume":"23","author":"Byonanebye","year":"2022","journal-title":"HIV Med"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103584_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1161\/HYPERTENSIONAHA.114.04394","article-title":"Burden of undiagnosed hypertension in Sub-Saharan Africa: a systematic review and meta-analysis","volume":"65","author":"Ataklte","year":"2015","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103584_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae139","article-title":"Sex-based disparities in the transition to dolutegravir-based antiretroviral therapy in West African HIV cohorts","volume":"11","author":"Tiendrebeogo","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.eclinm.2025.103584_bib22","series-title":"Guideline for the pharmacological treatment of hypertension in adults","first-page":"1","year":"2021"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103584_bib23","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/cid\/civ192","article-title":"Weight change after antiretroviral therapy and mortality","volume":"60","author":"Yuh","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"13","key":"10.1016\/j.eclinm.2025.103584_bib24","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/sim.9718","article-title":"Causal inference in survival analysis using longitudinal observational data: sequential trials and marginal structural models","volume":"42","author":"Keogh","year":"2023","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103584_bib25","first-page":"39","article-title":"Causal survival analysis: a guide to estimating intention-to-treat and per-protocol effects from randomized clinical trials with non-adherence","volume":"2","author":"Murray","year":"2021","journal-title":"Res Methods Med Health Sci"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103584_bib26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hern\u00e1n","year":"2000","journal-title":"Epidemiology"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103584_bib27","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103584_bib28","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/sim.8471","article-title":"A causal framework for classical statistical estimands in failure-time settings with competing events","volume":"39","author":"Young","year":"2020","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2025.103584_bib29","author":"Bates"},{"key":"10.1016\/j.eclinm.2025.103584_bib30","series-title":"Hadley Wickham. ggplot2","year":"2016"},{"key":"10.1016\/j.eclinm.2025.103584_bib31","author":"Ambler"},{"key":"10.1016\/j.eclinm.2025.103584_bib32","author":"Su"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103584_bib33","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1016\/S2352-3018(23)00233-3","article-title":"Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL collaboration and the antiretroviral therapy cohort collaboration","volume":"10","author":"Rein","year":"2023","journal-title":"Lancet HIV"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103584_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26216","article-title":"Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study","volume":"27","author":"Shamu","year":"2024","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103584_bib35","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/cid\/ciad297","volume":"77","author":"Sempere","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103584_bib36","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/jac\/dkaf212","article-title":"Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks","volume":"80","author":"Patel","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103584_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26371","article-title":"Impact of switching to a dolutegravir-based regimen on body weight changes: insights from West African adult HIV cohorts","volume":"27","author":"Tiendrebeogo","year":"2024","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103584_bib38","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.4102\/sajhivmed.v24i1.1500","article-title":"Weight gain on dolutegravir: association is not the same as causation","volume":"24","author":"Maartens","year":"2023","journal-title":"South Afr J HIV Med"},{"key":"10.1016\/j.eclinm.2025.103584_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101836","article-title":"Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa","volume":"57","author":"Brennan","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103584_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26268","article-title":"Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa","volume":"27","author":"Manne-Goehler","year":"2024","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103584_bib41","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/S2352-3018(23)00328-4","volume":"11","author":"Byonanebye","year":"2024","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103584_bib43","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1186\/s12889-020-09829-5","article-title":"Hypertension prevalence, awareness, treatment, and control and predicted 10-year CVD risk: a cross-sectional study of seven communities in East and West Africa (SevenCEWA)","volume":"20","author":"Okello","year":"2020","journal-title":"BMC Public Health"},{"key":"10.1016\/j.eclinm.2025.103584_bib44","series-title":"Risks of hypertension with first-line dolutegravir (DTG) and tenofovir alafenamide (TAF) in the NAMSAL and ADVANCE trials","author":"Venter","year":"2023"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025005176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025005176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:37:15Z","timestamp":1794346635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025005176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":42,"alternative-id":["S2589537025005176"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103584","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between transitioning to a dolutegravir-based regimen and risk of incident hypertension in adults with HIV in West Africa: a multicentre target trial emulation study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103584"}}